Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is an open-label extension allowing patients who have completed Protocol MNTX 301 to continue to receive SC MNTX.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Arm 1 | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| SC Methylnaltrexone (MNTX) | Drug |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of patients with adverse events | To provide access to continued treatment with MNTX administered SC, to patients who completed Progenics' MNTX 301. | 3 months |
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline in pain scores | To provide access to continued treatment with MNTX administered SC, to patients who completed Progenics' MNTX 301. | 3 months |
| Number of patients with opioid withdrawal symptoms |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Tage Ramakrishna, MD | Progenics Pharmaceuticals, Inc. | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Progenics Pharmaceuticals | Tarrytown | New York | 10591 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To provide access to continued treatment with MNTX administered SC, to patients who completed Progenics' MNTX 301.
| 3 months |